Cardinal Health and Telix Launch Gallium Awareness Campaign
Dublin (Ohio) and Indianapolis (Indiana) – 27 May 2021. Cardinal Health and Telix launch gallium awareness campaign with release of a white-paper entitled: “Moving beyond the Myth”.
In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the Myth”.
As interest and demand for more accurate prostate cancer imaging grows, and with the approval of the first Ga-68 PSMA based prostate imaging agent late last year, Cardinal Health Nuclear & Precision Health Solutions (Cardinal Health) and Telix Pharmaceuticals (US) Inc. (Telix) have developed an in-depth white-paper, entitled: “Moving beyond the Myth: Meeting the growing demand for Ga-68 radiopharmaceuticals.” The paper shines a light on the pathways for radio-isotope production, distribution and clinical application, as well as highlighting the extensive systems already in place to help ensure potential demand for Ga-68 imaging products is met.
Telix Chief Executive Officer, Dr. Christian Behrenbruch stated, “There is a perception in the industry that supply chain issues may limit the availability of gallium-based radiopharmaceuticals. Whilst this may have been true historically, this is no longer the case. The strength and power of gallium lies in its flexibility of production by either cyclotron or generator, offering greater opportunity for scale than other purely cyclotron-based isotopes. Subject to regulator approval, we look forward to offering state-of-the-art diagnostic imaging to U.S. men living with prostate cancer, and Cardinal Health’s radiopharmacy network and infrastructure will be vital in facilitating nationwide access.”
Cardinal Health President, Tiffany Olson added, “Patient and physician satisfaction is our top priority. Telix Pharmaceuticals is developing gallium-based innovations to advance prostate cancer imaging, and Cardinal Health is ready to help meet that demand.”
To read the full media release, please click here.
The white-paper is available for free download here.
To return to Telix’s homepage please click here.